Tag: investor

ST. PETERSBURG, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”) today announced that it will release the results of its operations for the second quarter 2025 after the market close on Tuesday, August 5, 2025. Michael Benstock, Chairman, President and Chief Executive Officer, and Mike Koempel, Chief Financial Officer, will host a teleconference at 5:00 pm Eastern Time that day to discuss the Company’s results.

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

BOCA RATON, FL, July 22, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it will publish its second quarter 2025 financial results and business outlook on its investor relations website at https://defidevcorp.com/investor?tab=Earnings on Tuesday, August 12, 2025, at approximately 4:00 p.m. Eastern Time.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or “the Company”) (NYSE: ANRO) and certain of its officers.

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

Acquisition further strengthens firm’s position among the largest national owners of IOS